



3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

Product Information

Monoclonal Anti- β -Amyloid Clone BAM-10

produced in mouse, purified immunoglobulin

Catalog Number **A3981**

Product Description

Monoclonal Anti- β -Amyloid (mouse IgG1 isotype) is derived from the BAM-10 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from a BALB/c mouse immunized with a synthetic β -amyloid peptide (1-40) (Gene ID: 351) conjugated to KLH. The isotype is determined using a double diffusion immunoassay using Mouse Monoclonal Antibody Isotyping Reagents, Catalog Number ISO2.

Monoclonal Anti- β -Amyloid reacts specifically with β -amyloid protein. The epitope recognized by the antibody resides within amino acid residues 1-12 of the β -amyloid protein. The antibody specifically stains amyloid plaques within the cortex, and amyloid deposits in blood vessels, in formic acid-treated, formalin-fixed, paraffin-embedded and Methacarn-fixed sections of human Alzheimer's disease (AD) brain tissue. The antibody is useful in immunohistochemistry, immunoblotting,³ ELISA, and competitive ELISA. It has been used to neutralize A β assemblies in brains of transgenic mice expressing a mutant form of amyloid precursor protein,¹ and for *in vivo* deep tissue imaging using near-IR optical spectrum.²

The β -amyloid precursor protein (APP) is cleaved sequentially by the proteolytic enzymes β -secretase (BACE1) and γ -secretase to produce β -amyloid (A β) peptides with the A β 1-42 and the A β 1-40 forms being the most prevalent. Secreted A β peptides are degraded either via a re-uptake mechanism followed by endosomal degradation, or by an extracellular insulin degrading enzyme. Extracellular accumulation of A β leads to the formation of aggregates, fibrils and eventually amyloid deposits called neuritic plaques, a hallmark of Alzheimer's disease (AD).⁴ Much of the AD research has focused on determining the underlying mechanism(s) of A β protein toxicity. Of the many proposed mechanisms, one possible mechanism of A β protein toxicity may be through calcium-mediated

neurotoxicity. A β peptides can increase calcium influx through voltage-gated calcium channels (N- and L-type), reduce the magnesium blockade of NMDA receptors to allow increased calcium influx, and can form a cation-selective ion channel after their incorporation into the cell membrane.⁵⁻⁷ Cation channels are induced by both nascent and globular A β peptides.⁸ Thus, A β peptides may elicit toxic effects prior to fibril formation. Evidence suggests that copper and zinc may modulate the structure of the pleomorphic A β peptides to induce either pore formation or peptide precipitation.⁹ In other models, it was found that the A β peptides exhibit superoxide dismutase activity thus producing hydrogen peroxidase that may be responsible for neurotoxicity.¹⁰

Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide as a preservative.

Antibody concentration: ~1.5 mg/mL

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

For extended storage, freeze at -20°C in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

Product Profile

Immunohistochemistry: a working concentration of 2.5-5 $\mu\text{g}/\text{mL}$ is recommended using formic acid treated, formalin-fixed and paraffin-embedded tissue sections of human Alzheimer disease (AD) brain tissue.

Note: In order to obtain the best results using various techniques and preparations, we recommend determining optimal working dilutions by titration.

References

1. Kotilinek, L.A., et al., *J. Neuro.*, **22**, 6331-6335 (2002).
2. Skoch, J., et al., *J. Biomed. Opt.*, **10**, 1-7 (2005).
3. Tan, J., et al., *Nature Neurosci.*, **5**, 1288-1293 (2002).
4. Law, A., et al., *Brain Res. Rev.*, **35**, 73-96 (2001).
5. Pearson, H.A., in: *Alzheimer's Disease: Methods and Protocols*, pp. 113-138, Ed.: Hooper, N.M., Humana Press, NJ (2000).
6. Kawahara, M., and Kuroda, Y., *Brain Res. Bulletin*, **53**, 389-397 (2000).
7. Zhu, Y.J., et al., *FASEB J.*, **14**, 1244-1254 (2000).
8. Bhatia, R., et al., *FASEB J.*, **14**, 1233-1243 (2000).
9. Curtain, C.C., et al., *J. Biol. Chem.*, **276**, 20466-20473 (2001)
10. Veurink, G., et al., *Ann. Hum. Biol.*, **30**, 639-667 (2003).

EK,KAA,PHC 05/07-1